Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: The Losartan Intervention for Endpoint reduction in hypertension study

Journal of Hypertension

Volumn 27, Issue 3, 2009, Pages 567-574

  Olsen, Michael Hecht ^a,p   Wachtell, Kristian ^b   Beevers, Gareth ^c   Dahlöf, Björn ^d   De Simone, Giovanni ^e   Devereux, Richard B ^f   De Faire, Ulf ^g   Fyhrquist, Frej ^h   Ibsen, Hans ^a   Kjeldsen, Sverre E ⁱ   Lederballe Pedersen, Ole ^j   Lindholm, Lars H ^k   Lyle, Paulette A ^l   Nieminen, Markku S ^h   Omvik, Per ^m   Oparil, Suzanne ⁿ   Wedel, Hans ^o  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c CITY HOSPITAL   (United Kingdom)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j VIBORG HOSPITAL   (Denmark)

^k UMEÅ UNIVERSITY   (Sweden)

^l MERCK RESEARCH LABORATORIES   (United States)

^m HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^o NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^p UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

Atenolol; Cardiovascular outcomes; Hypertension; Lipids; Losartan

Indexed keywords

ATENOLOL; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOSARTAN;

AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

EID: 67649562235     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831daf96     Document Type: Article

References (40)

1. Kuster GM, Amann FW, Neuenschwander C, Drexel H. High densitylipoprotein subfractions of patients using cardio-selective beta-blockers. Cardiovasc Drugs Ther 2002; 16:127-131.
2. Dimmitt SB, Williams PD, Croft KD, Beilin LJ. Effects of beta-blockers on the concentration and oxidizability of plasma lipids. Clin Sci 1998; 94:573-578.
3. Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993; 33:286-291.
4. Lithell HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14:203-209.
5. Weidmann P, de Court, Ferrari P. Effect of diuretics on the plasma lipid profile. Eur Heart J 1992; 13 (Suppl G):61-67.
6. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
7. Lakshman MR, Reda DJ, Materson BJ, Cushman WC, Freis ZZ. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on antihypertensive agents. Arch Intern Med 1999; 159:551-558.
8. Moan A, Hoieggen A, Seljeflot I, Risanger T, Arnesen H, Kjeldsen SE. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 1996; 14:1093-1097.
9. Derosa G, Cicero AF, Bertone G, Piccinni MN, Fogari E,Ciccarelli L, Fogari R. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. ClinTher 2004;26:1228-1236.
10. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost 2005; 11:139-146.
11. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366:907-913.
12. Dahlöf B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Hypertension 1998; 32:989-997.
13. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
14. Kristianson K, Fyhrquist F, Devereux RB, Kjeldsen SE, Lindholm LH, Lyle PA, et al. An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint reduction in hypertension study. Clin Ther 2003; 25:1186-1199.
15. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
16. Stimpel M, Koch B, Oparil S. Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). Cardiology 1998; 89:271-276.
17. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. Br J Clin Pharmacol 1995; 39:471-476.
18. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128:1177-1183.
19. Ram CV, Ames RP, Applegate WB, Burris JF, Davidov ME, Mroczek WJ. Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. Clin Cardiol 1994; 17:251-256.
20. De Cesaris R, Ranieri G, Filitti V, Andriani A, Lamontanara G. Glucose and lipid metabolism in essential hypertension: effects of diuretics and ACE-inhibitors. Cardiology 1993; 83:165-172.
21. Lerch M, Teuscher AU, Beissner P, Schneider M, Shaw SG, Weidmann P. Effects of angiotensin II-receptor blockade with losartan on insulin sensitivity, lipid profile, and endothelin in normotensive offspring of hypertensive parents. J Cardiovasc Pharmacol 1998; 31:576-580.
22. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, Ohnishi A, et al. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 2007; 30:1205-1210.
23. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, Kuss O, et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 2006; 114 (Suppl 1):I296-I301.
24. Chen J, Li D, Schaefer R, Mehta JL. Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 2006; 184:295-301.
25. Middeke M, Richter WO, Schwandt P, Holzgreve H. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther 1997; 35:231-234.
26. Bilous R.Will ASCOT change the form of antihypertensive therapy? Diabet Med 2006; 23:13-14.
27. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23:891-898.
28. Thompson PD, Cullinane EM, Nugent AM, Sady MA, Sady SP. Effect of atenolol or prazosin on maximal exercise performance in hypertensive joggers. Am J Med 1989; 86:104-109.
29. Herbertsson P, Fagher B. Effects of verapamil and atenolol on exercise tolerance in 5,000 m cross-country running: a double-blind cross-over study in normal humans. J Cardiovasc Pharmacol 1990; 16:23-27.
30. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001; 104:3046-3051.
31. Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Borgioni C, Filippucci L, et al. Prognostic value of lipoprotein fractions in essential hypertension. Blood Press 2004; 13:295-303.
32. Foody JM, Ferdinand FD, Pearce GL, Lytle BW, Cosgrove DM, Sprecher DL. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from The Cleveland Clinic Foundation. Circulation 2000; 102:III90-III94.
33. Weidmann P, de Court, Ferrari P, Bohlen L. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Pharmacol 1993; 22:S98-S105.
34. Bittner V. Nonhigh-density lipoprotein cholesterol: an alternate target for lipid-lowering therapy. Prev Cardiol 2004; 7:122-126.
35. Kazi D, Farmer JA. Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary. Curr Atheroscler Rep 2005; 7:88-94.
36. Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J 2002; 144:S33-S42.
37. Luchtefeld M, Bandlow N, Tietge UJ, Grote K, Pfeilschifter J, Kaszkin M, et al. Angiotensin II type 1-receptor antagonism prevents type IIA secretory phospholipase A2-dependent lipid peroxidation. Atherosclerosis 2007; 194:62-70.
38. Ferrario CM, Smith R, Levy P, Strawn W. The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. Am J Med Sci 2002; 323:17-24.
39. Kaplan M, Aviram M, Knopf C, Keidar S. Angiotensin II reduces macrophage cholesterol efflux: a role for the AT-1 receptor but not for the ABC1 transporter. Biochem Biophys Res Commun 2002; 290:1529-1534.
40. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105-1187.